The Gonzales Lab at UNR Med, led by Albert Gonzales, Ph.D., assistant professor of physiology and cell biology, spearheaded ...

Intermediate AMD: If you have intermediate AMD in one or both eyes, AREDS 2 supplements may help prevent it from turning into late-stage AMD, which causes significant vision loss. Late AMD in One Eye: ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

LifeArc Ventures, which invests in innovative early-stage life science companies as part of LifeArc, today announced substantial progress in 2024, with three new investments, several follow-on ...

What is red light therapy? Treatment with red light therapy involves exposure to red light at a very low dose in a hospital or clinic. It’s also called low-power laser therapy, soft laser therapy, ...

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

Brookline Capital Management upgraded shares of Cognition Therapeutics (NASDAQ:CGTX – Free Report) to a strong-buy rating in a report released on Monday morning,Zacks.com reports. Brookline Capital ...

Canaccord rates Opthea a buy with a $1.25 price target. But the broker thinks it could shoot as high as ... Read More The ...